BIIB•benzinga•
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Summary
Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga